Eltrombopag in adult patients with immune thrombocytopenia in the real-world in France, including off-label use before 6 months of disease duration: The multicenter, prospective ELEXTRA study.
作者信息
Moulis Guillaume, Germain Johanne, Rueter Manuela, Lafaurie Margaux, Aroichane Myriam, Comont Thibault, Mahévas Matthieu, Viallard Jean-François, Chèze Stéphane, Ebbo Mikaël, Audia Sylvain, Leclerc-Teffahi Soraya, Sommet Agnès, Beyne-Rauzy Odile, Michel Marc, Godeau Bertrand, Lapeyre-Mestre Maryse
机构信息
Department of Internal Medicine, Toulouse University Hospital, Toulouse, France.
Clinical Investigation Center, Toulouse University Hospital, Toulouse, France.
出版信息
Am J Hematol. 2022 Feb 1;97(2):E40-E44. doi: 10.1002/ajh.26404. Epub 2021 Dec 6.
Abstract
摘要
相似文献
1
Eltrombopag in adult patients with immune thrombocytopenia in the real-world in France, including off-label use before 6 months of disease duration: The multicenter, prospective ELEXTRA study.艾曲泊帕在法国真实世界中成年免疫性血小板减少症患者中的应用，包括疾病持续时间不足6个月时的超说明书用药：多中心前瞻性ELEXTRA研究
Am J Hematol. 2022 Feb 1;97(2):E40-E44. doi: 10.1002/ajh.26404. Epub 2021 Dec 6.
2
Eltrombopag in chronic idiopathic thrombocytopenic purpura.艾曲泊帕用于慢性特发性血小板减少性紫癜
Lancet. 2009 Feb 21;373(9664):607-8. doi: 10.1016/S0140-6736(09)60377-9.
3
Treatment of immune thrombocytopenia with eltrombopag in patients who had and who had not received prior rituximab: post-hoc analysis of the EXTEND study.在接受过和未接受过利妥昔单抗治疗的免疫性血小板减少症患者中使用艾曲泊帕进行治疗：EXTEND研究的事后分析
Br J Haematol. 2022 Jan;196(2):448-452. doi: 10.1111/bjh.17800. Epub 2021 Aug 30.
4
Severe cutaneous toxicity related to Eltrombopag.与艾曲泊帕相关的严重皮肤毒性。
Br J Haematol. 2013 Feb;160(3):412-4. doi: 10.1111/bjh.12126. Epub 2012 Nov 15.
5
Eltrombopag--an oral thrombopoietin agonist.艾曲波帕——一种口服促血小板生成素激动剂。
Eur Rev Med Pharmacol Sci. 2012 Jun;16(6):743-6.
6
Eltrombopag--a novel approach for the treatment of chronic immune thrombocytopenic purpura: review and safety considerations.艾曲波帕——治疗慢性免疫性血小板减少性紫癜的新方法：综述与安全性考量
Drug Des Devel Ther. 2010 Jul 21;4:139-45. doi: 10.2147/dddt.s8601.
7
Successful discontinuation of eltrombopag in one child with refractory primary immune thrombocytopenia and literature review.一名难治性原发性免疫性血小板减少症患儿成功停用艾曲泊帕并文献综述
Blood Coagul Fibrinolysis. 2019 Mar;30(2):71-74. doi: 10.1097/MBC.0000000000000794.
8
Management of primary immune thrombocytopenia in a real-world setting in Japan: eltrombopag versus corticosteroids.在日本真实环境下原发性免疫性血小板减少症的管理：艾曲波帕与皮质类固醇的对比。
Int J Hematol. 2021 Aug;114(2):152-163. doi: 10.1007/s12185-021-03149-z. Epub 2021 Apr 13.
9
Health-related quality of life in children with chronic immune thrombocytopenia treated with eltrombopag in the PETIT study.在 PETIT 研究中，接受艾曲波帕治疗的慢性免疫性血小板减少症儿童的健康相关生活质量。
Br J Haematol. 2019 Apr;185(1):102-106. doi: 10.1111/bjh.15732. Epub 2018 Dec 27.
10
Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial.依鲁替尼治疗儿童慢性免疫性血小板减少症（PETIT2）的随机、多中心、安慰剂对照试验。
Lancet. 2015 Oct 24;386(10004):1649-58. doi: 10.1016/S0140-6736(15)61107-2. Epub 2015 Jul 28.
引用本文的文献
1
Efficacy and safety of dapsone in adult primary immune thrombocytopenia.氨苯砜治疗成人原发性免疫性血小板减少症的疗效与安全性。
Blood Adv. 2025 Apr 22;9(8):1976-1983. doi: 10.1182/bloodadvances.2024014939.
2
Real-world experience of thrombopoietin receptor agonists in pediatric immune thrombocytopenia: a report from a Chinese tertiary children's hospital.血小板生成素受体激动剂在儿童免疫性血小板减少症中的真实世界经验：来自中国一家三级儿童医院的报告。
Transl Pediatr. 2024 Jun 30;13(6):889-896. doi: 10.21037/tp-24-48. Epub 2024 Jun 27.
3
Use of thrombopoietin receptor agonists in adults with immune thrombocytopenia: a systematic review and Central European expert consensus.成人免疫性血小板减少症中血小板生成素受体激动剂的应用：系统评价和中欧专家共识。
Ann Hematol. 2023 Apr;102(4):715-727. doi: 10.1007/s00277-023-05114-8. Epub 2023 Feb 24.
本文引用的文献
1
American Society of Hematology 2019 guidelines for immune thrombocytopenia.美国血液学会 2019 年免疫性血小板减少症治疗指南。
Blood Adv. 2019 Dec 10;3(23):3829-3866. doi: 10.1182/bloodadvances.2019000966.
2
Updated international consensus report on the investigation and management of primary immune thrombocytopenia.更新的原发性免疫性血小板减少症的调查和管理国际共识报告。
Blood Adv. 2019 Nov 26;3(22):3780-3817. doi: 10.1182/bloodadvances.2019000812.
3
Immune Thrombocytopenia.免疫性血小板减少症
N Engl J Med. 2019 Sep 5;381(10):945-955. doi: 10.1056/NEJMcp1810479.
4
Thrombopoietin receptor agonists: ten years later.血小板生成素受体激动剂：十年后。
Haematologica. 2019 Jun;104(6):1112-1123. doi: 10.3324/haematol.2018.212845. Epub 2019 May 9.
5
Risk factors for bleeding, including platelet count threshold, in newly diagnosed immune thrombocytopenia adults.新诊断的成人免疫性血小板减少症患者出血的风险因素，包括血小板计数阈值。
J Thromb Haemost. 2018 Sep;16(9):1830-1842. doi: 10.1111/jth.14227. Epub 2018 Aug 12.
6
Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group.成人及儿童免疫性血小板减少性紫癜术语、定义及疗效标准的标准化：国际工作组报告
Blood. 2009 Mar 12;113(11):2386-93. doi: 10.1182/blood-2008-07-162503. Epub 2008 Nov 12.
Zotero 插件